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S344 Poster Session IItransplantation (HSCT) remains one of the best options to cure T-
ALL. However, many patients cannot find an HLA-matched do-
nor. Our institute established a new protocol for haplo-identical
HSCT. Busulfan, cyclophosphamide, cytosine arabinoside and
methyl CCNU plus anti-thymocyte globulin was used for condi-
tioning therapy. Seventy-two patients diagnosed with T-ALL un-
derwent transplantation from haplo-identical donor family
members. Risk factor analysis are summarised in Table 1. The in-
cidence rates of grades II to IV acute graft versus host disease
(aGVHD) and of grades III and IV aGVHD were 49%612%
and 19%612%, respectively. The cumulative incidence rate for
chronic GVHD (cGVHD) at two years after HSCT was 41%6
12%. After a median follow-up of 12 months, fifteen patients had
relapsed, fourteen died from relapse, and forty-one patients were
still alive without disease recurrence. The probability of leuke-
mia-free survival (LFS) was 44.2%67.4% at three years.Patients
transplanted during their first complete remission (CR1 had a lower
relapse rate (18.8% vs. 37.5%, p 5 0.049, with a RR 5 0.247, p 5
0.007), a lower non-relapse mortality (NRM) rate (16.6% vs.
50.0%, p 5 0.046, with a RR 5 0.279, p 5 0.024) and better
LFS (54.8% vs 12.5%, p 5 0.001, with a RR 5 0.315, p 5
0.004) compared with patients transplanted beyond CR1. This
study confirmed that haplo-identical/mismatched HSCT could be
an alternative treatment choice for T-ALL.377
CORD BLOOD TRANSPLANTATION FROM UNRELATED DONORS VERSUS
STEM CELL TRANSPLANTATION FROM HLA-IDENTICAL SIBLING IN
ADULTS WITH PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEU-
KEMIA
Jaramillo, F., Sanz, J., Montesinos, P., Martinez-Cuadron, D.,
Lorenzo, I., Palau, J., Martin, G., Jarque, I., De La Rubia, J.,
Moscardo, F., Martinez, J., Sanz, M., Sanz, G. Hospital Universitario
La Fe, Valencia, Spain
Allogeneic stem cell transplantation (allo-SCT) is considered
the best post-remission therapy for patients with Ph+ALL. How-
ever, the application of this procedure is limited by the availabil-
ity of suitable HLA-compatible donors. Umbilical cord blood
transplantation (UCBT) from unrelated donors has emerged as
an alternative approach for patients lacking an HLA-matched
donor. This study compares the clinical outcome of 36 adults
with Ph+ALL who received either UCBT from unrelated donors
(n 5 25) or bone marrow or peripheral blood stem cell trans-
plantation (BMT/PSCT) from HLA-matched sibling donors
(n 5 11) at a single institution. From June 1999 to August
2010, all consecutive patients with Ph+ALL, except one who re-
ceived total body irradiation, received busulfan, thiotepa, and cy-
clophosphamide or fludarabine as myeloablative conditioning
regimen. Antithymocyte globulin was added in UCBT patients.
All patients received cyclosporine as graft-versus-host disease
prophylaxis, combined prednisone or mycophenolate mofetil in
UCBT or methotrexate in matched-sibling allo-SCT. Median
age was 33 years (range, 16-54) and 21 (58%) were males. At
time of transplantation, 28 (78%), 3 (8%) and 5 (14%) were in
first complete remission (CR), second or further CR and more
advanced phase of the disease, respectively. Patient and disease
characteristics were similar in both groups. Except for one pa-
tient undergoing UCBT that experienced primary graft failure,
all remaining patients engrafted. Myeloid engraftment was faster
in BMT/PSCT than UCBT (median 12 days vs 20 days; p\
0.01). With a median follow-up of surviving patients of 41
months (range 15-114), the 4-year CI of NRM for UCBT and
BMT/PSCT recipients was 36% and 9%, respectively (p 5
0.1), and the CI of relapse 22% and 64%, respectively (p 5
0.15). Disease-free survival at 4 years was 42% in UCBT and
27% in matched-sibling allo-SCT recipients; (p 5 0.6). Our
data suggest that for patients with Ph+ALL, UCBT from unre-
lated donors is a reasonable approach with efficacy similar to
that of BMT/PSCT from HLA-identical sibling.378
ALLOGENEIC STEM CELL TRANSPLANTATION FROM MATCHED RELATED
DONOR IN PATIENTS OVER THE AGE OF 55 YEARS AFTER REDUCED IN-
TENSITY CONDITIONING ASSOCIATING FLUDARABINE-IV BUSULFAN
AND RABBIT-ANTITHYMOCYTE GLOBULIN: A PROSPECTIVE MULTICEN-
TER PHASE II CLINICAL TRIAL WITH SOCIO ECONOMIC EVALUATION
Blaise, D.1, Mohty, M.2, Milpied, N.3, Lecorroller-Soriano, A.-G.4,
Fegueux, N.5, Furst, S.1, Chevallier, P.2, Tabrizi, R.3, Michallet, M.6,
Cahn, J.-Y.7, Bay, J.-O.8, El Cheikh, J.1, Faucher, C.1, Crocchiolo, R.1,
Boyer-Chammard, A.1, Castagna, L.9, Boher, J.-M.1 1 Institut Paoli
Calmettes, Marseille, France; 2CHU, Nantes, France; 3CHU, Pessac,
France; 4 Institut Paoli Calmettes, Marseille, France; 5CHU,Montpellier,
France; 6CHU, Lyon, France; 7CHU, Grenoble, France; 8CHU, Cler-
mont-Ferrand, France; 9Humanitas, Milan, Italy
Weprospectively assess, in pts over 55years, eligible for anmatched
sibling Allo-SCT, the impact of a RIC with Fludarabine (30 mg/m2/
day (D-5 toD-1)), IVBusulfan (0.8mg/kg x 4/day (D-4 toD-3)) and r-
ATG (2.5 mg/kg/day (D-2 to D-1). Eventually, from 03/07 to 06/10,
82 pts have been included, of which 79 have been transplanted. Me-
dian follow-up is 24 months (10-50). All grafts were PBSC from
aHLA identical sibling. CSA (2mg/kg) was started on day -2.Median
age is 60 (55-70). Karnofsky score was 90 (60-90). Diagnoses: AML5
32;MDS5 13; ALL5 6; NHL5 10;MM5 13; Others5 5); 54 pts
were in CR (CR15 31; CR25 15; CR.25 8), 22 in PR or SD and 3
inPDafter amedianof 2 (1-7) lines of chemotherapy.All pts engrafted
and 46 presented with aGVHD (G1 n5 32; G2: n5 7; G3-4: n5 6)
for a 17% (10-23) cumulative incidence of G$ 2 aGVHD. A total of
47 pts had cGVHD (Limited: N5 28; extensive: N5 19) at a median
of 4.5 months (3-21) for a one year overall and extensive cumulative
incidence of 57% (46-68) and 34% (25-45) respectively. 12 pts died
from NRM. The 6 month and overall cumulative incidences of
NRM were 5% (0-10) and 16% (9-23) respectively. Karnofsky score
was not predictive ofNRM. 25 pts relapsed at a median of 4.2months
(0.8-12) for a cumulative incidence of 32% (23-42). Relapse incidence
differed according to disease pre-transplant status (9 of 46 CR1/CR2
vs. 16 of 33 beyond CR2 pts; p 5 0.008). Three year overall and dis-
ease-free survival probabilities were 79% (67-87) and 59% (45-71) re-
spectively. Considering the CR1 AML population (N5 21), median
age was 61 years (56-70) and probabilities of NRM, relapse, OS and
LFS were 14% (IC95 5 0-27), 14% (IC95 5 2-26), 72% (IC95 5
47-86) and 67 % (IC955 43-83) respectively. Economic data cover-
ing transplant and first 18 month post-transplant periods have been
prospectively collected and are under analysis. HRQL (Health Re-
lated Quality of Life) was assessed over a 1-year period with the
EORTC QLQ-C30 questionnaire (Days -7, +80, +180, +360). The
lowest functioning scores and highest symptom scores were experi-
enced 80 days after transplantation. Thereafter the level of function-
ing and level of symptoms returned to baseline levels, which is
reassuring in this population. Taking account patient characteristics,
results confirm that Allo-SCT after RIC is a valid option in this pop-
ulation, that RI. Further refining of this association, by cautious tun-
ing of the IV Busulfan dose, is under process in our program.379
FLUDARABINE AND CYCLOPHOSPHAMIDE PROVIDE A NON-MYELOA-
BLATIVE ALTERNATIVE CONDITIONING REGIMEN WITH LOW TRANS-
PLANT-RELATED MORTALITY AND CONTROL OF HIGH RISK DISEASE
Paplham, P., Hahn, T., Brown, K., Syta, M., Dubel, K., Lipka, P.,
McCarthy, P. Roswell Park Cancer Institute, Buffalo, NY
Myeloablative allogeneic hematopoietic cell transplant (MAT)
regimens are associated with significant transplant-related mortality
(TRM). Non-myeloablative (NMAT) regimens have a curative po-
tential for patients who would not be considered MAT candidates
due to factors such as older age, co-morbidities, prior failed MAT
or poor Karnofsky Performance Score (KPS). We performed a pro-
spective phase II clinical trial of a NMAT regimen with the objec-
tives to determine TRM, progression-free (PFS) and overall
survival (OS). Forty patients were enrolled April 2002 - December
2008 at a single center and received cyclophosphamide 50 mg/kg/d
Poster Session II S345x 2 and fludarabine 25 mg/m2/d x 5 (FluCy) for NMAT.Methotrex-
ate 5 mg/m2 on days +1, +3 and +6, mycophenolate mofetil day -1 to
+60 and tacrolimus day -1 to off by +180 was the GvHD prophylaxis
regimen in 90%. Patient characteristics at NMAT included: male
(n 5 24), female (n 5 16), median (range) age 52 (21-71) yrs, KPS
90-100 (n 5 12), KPS 50-80 (n 5 28), NHL (n 5 12), AML (n 5
10), HL (n 5 8), MDS (n 5 5), ALL (n 5 2), MM (n 5 2), PLL
(n5 1),HLA-matched related donor (n5 14), 7/8HLA-mismatched
related donor (n 5 1), HLA-matched unrelated donor (n 5 15),
HLA-mismatched unrelated donor (n 5 9 at 9/10 and n 5 1 at
8/10), complete remission (CR, n 5 11), no prior CR (n 5 12), and
relapsed disease (n 5 17). Prior transplants included autologous
(N 5 19) and allogeneic (N 5 2). The TRM cumulative incidence
at Day +100 and 1-yr post NMAT was 13% (CI 1-25%) and 34%
(CI 17-51%) respectively.Overall,TRMdeathswere due to infection
(n5 8), GvHD (n5 2), regimen-related toxicity (n5 2), hemorrhage
(n5 1). OS estimates at Day +100, 1-yr, and 3-yrs post NMATwere
80% (CI 68-92%), 43% (CI 27-58%), and 19% (CI 7-32%) respec-
tively. OS was improved in patients with KPS 90-100 (1 yr OS 58%
vs. 36%, p 5 0.04) but worse in recipient/donor CMV +/- vs. other
combinations (1 yr OS 8% vs. 59%, p 5 0.001). PFS at Day +100,
1-yr, and 3-yrs was 65% (CI 50-80%), 25% (CI 12-38%), and 14%
(CI 3-25%) respectively. Patients with advanced disease, defined by
CIBMTR criteria http://www.cibmtr.org/ReferenceCenter/Slides
Reports/SummarySlides/pages/index.aspx, had Day +100 PFS 54%
(CI 24-74%) with PFS 21% (CI 6-40%) at both 1-and 2-yrs. FluCy
has a low rate ofTRMand is curative in about 1/5 of advanced disease
patients. Identification of pre-NMAT factors, which predict for long
term survival after FluCymay allow for appropriate patient selection
for FluCy versus alternative NMAT regimens.
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BOOSTER INFUSION OF T-CELL DEPLETED, CD34+ ENRICHED, DONOR
CELLS RESULTS IN SUSTAINED COUNT RECOVERY FOR PATIENTS
WITH POOR GRAFT FUNCTION FOLLOWING ALLOGENEIC STEM CELL
TRANSPLANTATION
Ramsingh, G., Rettig, M., Gabriel, J., Westervelt, P., Uy, G.L.,
Abboud, C.N., DiPersio, J.F. Washington University in St. Louis, St.
Louis, MO
Poor graft function following allogeneic stem cell transplantation
(ASCT) isdefinedbycytopenias in thepresenceof completedonoren-
graftment. Infusion of unselected donor hematopoietic stem cells
(HSC) can improve cytopenias but may increase graft versus host dis-
ease (GVHD). Here we conducted a single institution prospective
study to investigate the feasibility of using ‘‘booster’’ infusions of T-
cell depleted, CD34+ enriched donor peripheral blood mononuclear
cells mobilized using G-CSF +/- plerixafor to improve the blood
counts and decrease transfusion requirements in patients with poor
graft function following ASCT. Patients age .18 years who were at
least 60 days post ASCT with persistent cytopenia (Platelets
\20,000/mm3 or ANC\500,000/mm3, transfusion dependent or in-
adequate response tohematopoietic growth factors.30days)withno
reversible etiology were included in the study. Only patients with do-
nor chimerism of$90% were included in the study. To date we have
enrolled a total of 6 patients (1 unrelated, 5 related), Age range 25-68
(mean56.5),Male: Female ratio 1:1.One relateddonorwithdrewcon-
sent after enrolling. All 5 patients had platelet counts below 20,000
/mm3 and were platelet transfusion dependent with 1 patient also re-
quiring RBC transfusions. Unrelated donor stem cell were mobilized
using standardNMDPguidelines and related usingGCSF+Plerixafor
(GCSF 10mcg/KgSC x 5 days followed by plerixafor 320mcg/Kg IV
four hour prior to mobilization). CD34+ cells were selected from the
leukapharesis product usingCliniMACS (Miltenyi) and infused to the
recipientwithout conditioning.All products contained.99%CD34+
cells with\0.01% T-cells. A median of 12.5x106 (range 3.1x106 -
23.9x106) CD34+ cells per patient were obtained. No donor or recip-
ient toxicity related to the procedure or worsening of GVHD was
observed. 4patients achieved transfusion independencewith sustained
response in 3 (follow up 7-365 days).Median time to platelet recovery
was 26 days (range 14-62). 2 patients died (1 disease relapse, 1 unex-
plained cause). This study shows the feasibility of administering
‘booster’ CD34+ selected cells fromdonor for poor graft function fol-
lowing ASCT, with minimal toxicity and durable response. A larger
study to evaluate efficacy is warranted.381
ALLOGENEIC TRANSPLANTATION IN ADULT ALL: CLINICAL EQUIPOISE
IN CANADA
Paulson, K.1, Raymond, C.2, Szwajcer, D.1, Wall, D.A.1, Seftel, M.D.1
1University of Manitoba, Winnipeg, MB, Canada; 2University of Mani-
toba, Winnipeg, MB, Canada
Introduction: Adults with acute lymphoblastic leukemia (ALL) in
first complete remission (CR1) may be treated with chemotherapy
or allogeneic hematopoietic stem cell transplantation (alloHCT).
The MRC/ECOG trial1 demonstrated a survival benefit to standard
risk patients with a matched sibling donor (MSD). However, pediat-
ric inspired chemotherapy, reduced intensity conditioning (RIC), and
alternative stem cell sources have renewed controversy about the role
of alloHCT in CR1.We hypothesized that Canadian physicians who
treat adult ALL would demonstrate wide practice variation.
Methods: Physician members of the Canadian Blood and Marrow
Transplant Group (CBMTG) and hematologists at all university-
based medical centres in Canada were contacted via email with a val-
idated electronic survey in May 2011.
Results: 69 of 173 physicians surveyed responded(40%). Themajor-
ity of respondents worked at centres that saw fewer than 20 adult
ALL patients annually. While there was high agreement with al-
loBMT in CR1 high risk cytogenetics or induction failure after a sin-
gle chemotherapy course (91.7% and 87.5%, respectively), only
45.9% and 19.3% felt that age .35 and T cell immunophenotype
would be indications for alloHCT in CR1. High WBC (.30 for
B-Cell, .100 for T-Cell) was felt to be an indication for alloHCT
by 81.2% of respondents. Respondents felt that the presence of min-
imal residual disease (MRD) was a strong indication for alloHCT
(63.8% agree), although most (66.7% agree) did not have access to
MRD testing. Most (96%) felt that a well matched unrelated donor
was an acceptable alternative to aMSD.There was uncertainty about
the role of cord blood as an appropriate cell source (53.2% agree) and
the utility of reduced intensity alloHCT (RIC alloHCT) (41%
agree). The strongest agreement was on the role of AlloHCT in Phil-
adelphia positive ALL (98% agree).
Conclusions: In Canada, there is substantial disagreement about in-
dications for alloHCT in adult ALL in CR1. Respondents felt that
alloHCTwas particularly helpful in high-risk patients, contradicting
the results of the MRC/ECOG study. The t(9;22) was felt to be
a strong indication for transplant. Consensus was lacking on the
use of cord blood or RIC alloHCT. Although MRD testing was
thought to be a useful guide to planning therapy, it was not widely
available. Equipoise exists on the role of alloHCT in CR1 in ALL,
suggesting further trials in this area are needed.
1 – Goldstone et al, Blood, 2008.
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SELF COLLECTION OF NASAL SWABS FOR DIAGNOSIS OF RESPIRATORY
VIRUSES IN IMMUNOCOMPETENT VOLUNTEERS AND HEMATOPOIETIC
STEM CELL TRANSPLANT (HCT) RECIPIENTS
Campbell, A.P.1,2,3, Kuypers, J.2,3, Callais, C.L.3, Guthrie, K.A.3,
Englund, J.A.1,2,3, Boeckh, M.2,3 1Seattle Children’s Hospital, Seattle,
WA; 2University of Washington, Seattle, WA; 3Fred Hutchinson Cancer
Research Center, Seattle, WA
Background:We previously developed a method for self collection
of nasal swab samples and demonstrated that self-collected swabs
were sensitive (sensitivity 96%) compared with staff-collected nasal
washes (sensitivity 88%) for detection of respiratory viruses (RVs)
by PCR in 152 collections from immunocompetent volunteers
with new upper respiratory infections (URIs). Our self-collection
method employed saline spray delivered by a metered spray bottle
and a polyurethane foam swab, but many current protocols advocate
use of dry respiratory swabs. In the present study, we compare collec-
tion of swabs with and without use of saline spray in both immuno-
competent volunteers and HCT recipients.
Methods: Immunocompetent volunteers with new URI completed
a symptom survey and performed self collection in one naris using
saline spray and a polyurethane foam swab (‘‘wet’’), and in the oppo-
site naris using a swab alone (‘‘dry’’). HCT recipients with a docu-
mented virologically-positive URI completed a symptom survey
and collection procedure within 1 week of initial diagnosis; these
subjects were followed weekly as feasible until negative. Swabs
